New research uncovers significant sensory impacts of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications commonly prescribed for weight loss and obesity management. Researchers at the University of Pennsylvania found that GLP-1 RAs significantly impair taste function across all five basic taste qualities: sweet, sour, salty, bitter, and umami. Their findings shed light on a previously underexplored consequence of these drugs.
